Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:EOLS NASDAQ:GNFT NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.08$1.97$1.60▼$2.54$802.22M1.031.35 million shs1.45 million shsEOLSEvolus$9.66+4.3%$9.85$8.67▼$17.82$597.04M0.97757,745 shs898,693 shsGNFTGENFIT$3.71+0.7%$4.12$2.55▼$6.42$184.01M1.0810,456 shs694 shsNUVBNuvation Bio$2.38+16.1%$2.14$1.54▼$3.97$697.54M1.333.02 million shs13.92 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%+4.00%+6.12%+23.81%-7.14%EOLSEvolus+4.32%+4.89%+0.10%+2.66%-13.52%GNFTGENFIT+0.71%-2.60%-12.80%+13.68%-12.18%NUVBNuvation Bio+16.10%+15.82%-5.18%+35.61%-25.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group2.2554 of 5 stars0.05.00.00.01.90.02.5EOLSEvolus3.692 of 5 stars3.50.00.03.51.13.30.6GNFTGENFIT1.5002 of 5 stars3.54.00.00.00.00.00.0NUVBNuvation Bio3.4645 of 5 stars4.60.00.00.03.34.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AEOLSEvolus 3.00Buy$23.75145.86% UpsideGNFTGENFIT 3.00Buy$13.00250.78% UpsideNUVBNuvation Bio 3.20Buy$7.17201.12% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, NUVB, CRON, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.006/2/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.005/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/23/2025NUVBNuvation BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025NUVBNuvation BioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$6.004/23/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$6.004/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$124.59M6.44$0.00 per share4,470.04$2.90 per share0.72EOLSEvolus$266.27M2.34N/AN/A$0.09 per share107.33GNFTGENFIT$67.00M2.77$0.07 per share52.61$1.50 per share2.47NUVBNuvation Bio$7.87M102.90N/AN/A$1.37 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1316.0069.33N/A39.69%-0.07%-0.07%8/6/2025 (Estimated)EOLSEvolus-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)NUVBNuvation Bio-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/4/2025 (Estimated)Latest GNFT, NUVB, CRON, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025NUVBNuvation Bio-$0.17N/AN/AN/A$0.42 millionN/A7/30/2025Q2 2025EOLSEvolus-$0.09N/AN/AN/A$82.18 millionN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75EOLSEvolus22.002.342.16GNFTGENFIT0.081.231.23NUVBNuvation BioN/A9.019.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%EOLSEvolus90.69%GNFTGENFIT2.24%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%EOLSEvolus5.90%GNFTGENFIT4.20%NUVBNuvation Bio29.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million357.53 millionOptionableEOLSEvolus17064.48 million60.67 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableNUVBNuvation Bio60340.26 million238.42 millionOptionableGNFT, NUVB, CRON, and EOLS HeadlinesRecent News About These CompaniesAnalysts Set Nuvation Bio Inc. (NYSE:NUVB) PT at $7.173 hours ago | americanbankingnews.comAll You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to BuyJuly 9 at 1:01 PM | zacks.comNuvation Bio (NYSE:NUVB) Shares Gap Up - What's Next?July 9 at 12:16 PM | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 7 at 4:10 AM | marketbeat.comNuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo FinanceJuly 2, 2025 | uk.finance.yahoo.comNuvation Bio (NYSE:NUVB) Stock Price Up 8% - Time to Buy?June 30, 2025 | marketbeat.comJMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch PlansJune 29, 2025 | msn.comNuvation Bio (NYSE:NUVB) Sees Strong Trading Volume - Here's What HappenedJune 25, 2025 | marketbeat.comNuvation Bio's (NUVB) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJune 25, 2025 | marketbeat.comRBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy RatingJune 24, 2025 | msn.comNuvation Bio jumps after insiders purchase shares worth over $1.1MJune 20, 2025 | msn.comNuvation Bio (NYSE:NUVB) Shares Gap Up - Here's WhyJune 20, 2025 | marketbeat.comFounder of Nuvation Bio David Hung Buys More StockJune 20, 2025 | finance.yahoo.comNuvation Bio price target lowered to $6 from $10 at RBC CapitalJune 18, 2025 | investing.comNuvation Bio: A Justified Fall Based On Post-Marketing RequirementsJune 18, 2025 | seekingalpha.comRoyal Bank of Canada Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock PriceJune 17, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Shares Gap Down - Time to Sell?June 16, 2025 | marketbeat.comOnco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.June 16, 2025 | globenewswire.comNuvation Bio price target maintained at $6 by Citizens JMPJune 14, 2025 | investing.comNuvation Bio’s SWOT analysis: FDA approval boosts stock prospectsJune 14, 2025 | investing.comNuvation Bio (NYSE:NUVB) Downgraded to "Sell" Rating by Wall Street ZenJune 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesMicron Insiders Sell But Investors Should Buy, Buy, BuyBy Thomas Hughes | July 7, 2025View Micron Insiders Sell But Investors Should Buy, Buy, Buy3 Tech Stocks Poised for Explosive EPS Growth in 2025By Gabriel Osorio-Mazilli | July 8, 2025View 3 Tech Stocks Poised for Explosive EPS Growth in 2025Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingBy Thomas Hughes | June 26, 2025View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingMicron’s Big Q3 Drives Applied Materials’ Bullish OutlookBy Leo Miller | July 3, 2025View Micron’s Big Q3 Drives Applied Materials’ Bullish OutlookMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment GNFT, NUVB, CRON, and EOLS Company DescriptionsCronos Group NASDAQ:CRON$2.08 0.00 (0.00%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$2.09 +0.01 (+0.48%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Evolus NASDAQ:EOLS$9.66 +0.40 (+4.32%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$9.68 +0.02 (+0.16%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.GENFIT NASDAQ:GNFT$3.71 +0.03 (+0.71%) As of 07/9/2025 12:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Nuvation Bio NYSE:NUVB$2.38 +0.33 (+16.10%) Closing price 07/9/2025 03:57 PM EasternExtended Trading$2.39 +0.01 (+0.59%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.